Treatment completion rates with tirzepatide in adults with obesity: a systematic review and meta-analysis of randomized and real-world studies
Romanian Medical Journal · 30.06.2026 · 73 (2) · 285
DOI: 10.37897/rmj.2026.2.12 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Romanian Medical Journal, online erschienen am 19.06.2026. Verfasst von Limna Mahaboob und 4 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tirzepatide has demonstrated substantial weight-loss efficacy in randomized controlled trials (RCTs) of adults with obesity. However, treatment completion is required to sustain cardiometabolic benefits. No previous meta-analysis has quantified treatment completion rates specifically in tirzepatide obesity RCTs.
Methods
This PRISMA 2020-guided systematic review and meta-analysis searched PubMed/MEDLINE, Embase, Scopus, Web of Science, Google Scholar, and ClinicalTrials.gov from inception to February 2026. Phase 2/3 RCTs evaluating tirzepatide in adults with overweight or obesity, defined as BMI ≥27 kg/m² with comorbidities or BMI ≥30 kg/m², were eligible. The primary outcome was treatment completion, defined as the proportion of randomized participants completing the full trial protocol at ≥24 weeks. Secondary outcomes included all-cause discontinuation and discontinuation due to adverse events. Random-effects meta-analysis was performed using a generalized linear mixed model with a logit link, and risk of bias was assessed using RoB 2.
Results
Four SURMOUNT RCTs, including 4,119 participants in tirzepatide arms, were analyzed. Trial-level completion rates ranged from 79.1% to 89.2%. Overall, 3,596 of 4,119 participants completed treatment, corresponding to a pooled completion rate of 87.3% (95% CI: 82.2–88.9%), with no observed heterogeneity (I² = 0.0%). Gastrointestinal adverse events were the most common reason for discontinuation, accounting for approximately 5–7% of discontinuations in tirzepatide arms. Overall risk of bias was low or raised some concerns across trials.
Conclusions
Tirzepatide showed high treatment completion rates and generally favorable tolerability in obesity RCTs. These findings are limited to trial settings, and real-world persistence should be evaluated separately.
Zitieren
APA
Mahaboob, L., Shehab, A., Buraiki, H. A., Iblasi, A. K. S. H., & Farghaly, W. K. T. (2026). Treatment completion rates with tirzepatide in adults with obesity: a systematic review and meta-analysis of randomized and real-world studies. Romanian Medical Journal, 73(2), 285. https://doi.org/10.37897/rmj.2026.2.12
Vancouver
Mahaboob L, Shehab A, Buraiki HA, Iblasi AKSH, Farghaly WKT. Treatment completion rates with tirzepatide in adults with obesity: a systematic review and meta-analysis of randomized and real-world studies. Romanian Medical Journal. 2026;73(2):285. doi:10.37897/rmj.2026.2.12
BibTeX
@article{Mahaboob2026,
author = {Mahaboob, Limna and Shehab, Abdullah and Buraiki, Hassan Al and Iblasi, Abdul Kareem Suhel Hamadeh and Farghaly, Walaa Kamel Tawfik},
title = {Treatment completion rates with tirzepatide in adults with obesity: a systematic review and meta-analysis of randomized and real-world studies},
journal = {Romanian Medical Journal},
year = {2026},
volume = {73},
number = {2},
pages = {285},
doi = {10.37897/rmj.2026.2.12}
}
EUVIMED